Cargando…
Botulinum toxin type A for neuropathic pain in patients with spinal cord injury
OBJECTIVE: To evaluate the analgesic effect of botulinum toxin type A (BTX‐A) on patients with spinal cord injury‐associated neuropathic pain. METHODS: The effect of BTX‐A on 40 patients with spinal cord injury‐associated neuropathic pain was investigated using a randomized, double‐blind, placebo‐co...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825405/ https://www.ncbi.nlm.nih.gov/pubmed/26814620 http://dx.doi.org/10.1002/ana.24605 |
_version_ | 1782426214687834112 |
---|---|
author | Han, Zee‐A Song, Dae Heon Oh, Hyun‐Mi Chung, Myung Eun |
author_facet | Han, Zee‐A Song, Dae Heon Oh, Hyun‐Mi Chung, Myung Eun |
author_sort | Han, Zee‐A |
collection | PubMed |
description | OBJECTIVE: To evaluate the analgesic effect of botulinum toxin type A (BTX‐A) on patients with spinal cord injury‐associated neuropathic pain. METHODS: The effect of BTX‐A on 40 patients with spinal cord injury‐associated neuropathic pain was investigated using a randomized, double‐blind, placebo‐controlled design. A 1‐time subcutaneous BTX‐A (200U) injection was administered to the painful area. Visual analogue scale (VAS) scores (0–100mm), the Korean version of the short‐form McGill Pain Questionnaire, and the World Health Organization WHOQOL‐BREF quality of life assessment were evaluated prior to treatment and at 4 and 8 weeks after the injection. RESULTS: At 4 and 8 weeks after injection, the VAS score for pain was significantly reduced by 18.6 ± 16.8 and 21.3 ± 26.8, respectively, in the BTX‐A group, whereas it was reduced by 2.6 ± 14.6 and 0.3 ± 19.5, respectively, in the placebo group. The pain relief was associated with preservation of motor or sensory function below the neurological level of injury. Among the responders in the BTX‐A group, 55% and 45% reported pain relief of 20% or greater at 4 and 8 weeks, respectively, after the injection, whereas only 15% and 10% of the responders in the placebo group reported a similar level of pain relief. Improvements in the score for the physical health domain of the WHOQOL‐BREF in the BTX‐A group showed a marginal trend toward significance (p = 0.0521) at 4 weeks after the injection. INTERPRETATION: These results indicate that BTX‐A may reduce intractable chronic neuropathic pain in patients with spinal cord injury. Ann Neurol 2016;79:569–578 |
format | Online Article Text |
id | pubmed-4825405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48254052016-04-18 Botulinum toxin type A for neuropathic pain in patients with spinal cord injury Han, Zee‐A Song, Dae Heon Oh, Hyun‐Mi Chung, Myung Eun Ann Neurol Research Articles OBJECTIVE: To evaluate the analgesic effect of botulinum toxin type A (BTX‐A) on patients with spinal cord injury‐associated neuropathic pain. METHODS: The effect of BTX‐A on 40 patients with spinal cord injury‐associated neuropathic pain was investigated using a randomized, double‐blind, placebo‐controlled design. A 1‐time subcutaneous BTX‐A (200U) injection was administered to the painful area. Visual analogue scale (VAS) scores (0–100mm), the Korean version of the short‐form McGill Pain Questionnaire, and the World Health Organization WHOQOL‐BREF quality of life assessment were evaluated prior to treatment and at 4 and 8 weeks after the injection. RESULTS: At 4 and 8 weeks after injection, the VAS score for pain was significantly reduced by 18.6 ± 16.8 and 21.3 ± 26.8, respectively, in the BTX‐A group, whereas it was reduced by 2.6 ± 14.6 and 0.3 ± 19.5, respectively, in the placebo group. The pain relief was associated with preservation of motor or sensory function below the neurological level of injury. Among the responders in the BTX‐A group, 55% and 45% reported pain relief of 20% or greater at 4 and 8 weeks, respectively, after the injection, whereas only 15% and 10% of the responders in the placebo group reported a similar level of pain relief. Improvements in the score for the physical health domain of the WHOQOL‐BREF in the BTX‐A group showed a marginal trend toward significance (p = 0.0521) at 4 weeks after the injection. INTERPRETATION: These results indicate that BTX‐A may reduce intractable chronic neuropathic pain in patients with spinal cord injury. Ann Neurol 2016;79:569–578 John Wiley and Sons Inc. 2016-02-16 2016-04 /pmc/articles/PMC4825405/ /pubmed/26814620 http://dx.doi.org/10.1002/ana.24605 Text en © 2016 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Han, Zee‐A Song, Dae Heon Oh, Hyun‐Mi Chung, Myung Eun Botulinum toxin type A for neuropathic pain in patients with spinal cord injury |
title | Botulinum toxin type A for neuropathic pain in patients with spinal cord injury |
title_full | Botulinum toxin type A for neuropathic pain in patients with spinal cord injury |
title_fullStr | Botulinum toxin type A for neuropathic pain in patients with spinal cord injury |
title_full_unstemmed | Botulinum toxin type A for neuropathic pain in patients with spinal cord injury |
title_short | Botulinum toxin type A for neuropathic pain in patients with spinal cord injury |
title_sort | botulinum toxin type a for neuropathic pain in patients with spinal cord injury |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825405/ https://www.ncbi.nlm.nih.gov/pubmed/26814620 http://dx.doi.org/10.1002/ana.24605 |
work_keys_str_mv | AT hanzeea botulinumtoxintypeaforneuropathicpaininpatientswithspinalcordinjury AT songdaeheon botulinumtoxintypeaforneuropathicpaininpatientswithspinalcordinjury AT ohhyunmi botulinumtoxintypeaforneuropathicpaininpatientswithspinalcordinjury AT chungmyungeun botulinumtoxintypeaforneuropathicpaininpatientswithspinalcordinjury |